Ergoteles’s Zevra Therapeutics ZVRA Stock Holding History

Ergoteles’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,580	Closed	-$76.1K	–	1819
2022 Q4	$76.1K	Sell	16,580 -105,420	-86%	-$535K	﹤0.01%	1254
2022 Q3	$761K	Sell	122,000 -22,400	-16%	-$127K	0.03%	597
2022 Q2	$644K	Buy	+144,400	New	+$658K	0.02%	723

Other funds holding ZVRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Ergoteles's ZVRA Position: Q1 2023 in Review

Ergoteles sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 16,580 shares — an estimated $76.1K sold.

Ergoteles first reported a position in ZVRA in Q2 2022 and held it in 3 quarters. The position peaked at $761K in Q3 2022. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

Ergoteles reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 16,580 Zevra Therapeutics shares in Q1 2023, an estimated $76.1K.
Ergoteles first reported a position in Zevra Therapeutics in Q2 2022 and held it in 3 quarters.
Ergoteles's Zevra Therapeutics position peaked at $761K in Q3 2022.
60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.